sur Nyxoah SA. (isin : BE0974358906)
Nyxoah Reports Third Quarter 2024 Financial Results
On November 6, 2024, Nyxoah SA released its third-quarter financial results, highlighting a 30% increase in sales compared to the same period last year, reaching €1.3 million. The company, focused on developing neuromodulation treatments for Obstructive Sleep Apnea (OSA), is preparing for a U.S. commercial launch upon anticipated FDA approval in the first quarter of 2025.
Key achievements include raising €24.6 million to extend its cash runway until mid-2026 and strengthening its U.S. team with new leadership. Despite increased expenses from research and development and commercial activities, Nyxoah maintains a solid cash position of €71.0 million, demonstrating financial resilience as it advances towards potential U.S. market entry.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Nyxoah SA.